drugset / Trial / NCT00755807
Duloxetine for Multiple Sclerosis Pain
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple Sclerosis.
Timeline
- Start
- 2008-10
- Primary completion
- 2010-08
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duloxetine | Small molecule | 60 mg | Oral |
| Subject | Duloxetine | Small molecule | 90 mg | Oral |
| Subject | Duloxetine | Small molecule | 120 mg | Oral |